For clinical operations teams at sponsors and CROs
Clinical Trial Oversight
Configured to your study. Read-only next to your EDC.
- 100+Sites live
- 8Countries
- 3–6 wksTo go live, also mid-study
Configured, not guessed
Your process. Configured.
Your categories
Your PD spreadsheet, built in.
Your roles
Who reports, reviews and signs off.
Your notifications
Every change reaches the right inbox.
Not AI. Your rules.
Your next data review meeting
Pick one.
Without Vera
- ✕Deviations in EDC, Excel and paper
- ✕PD examples v4 FINAL
- ✕A case was downgraded. Nobody told you.
With Vera
- ✓One record
- ✓Your categories, built in
- ✓You are told, every time
Vera Platform
Clinical trial oversight, before and during your study
Clinical trial oversight for sponsors and CROs, from the first patient to the final decision.
During the trial
Vera Deviate™
One signed-off record for every deviation.
Learn more about our protocol deviation management software →Before first patient in
Vera Simulate™
Test patient materials with families.
Explore Vera Simulate →Could you show an inspector who decided?
10 questions. 5 minutes.
How each question is tagged
- FDA regulationBinding law: informed consent and IRB rules (21 CFR 50 and 56)
- ICH E6(R3)Expected under the current GCP standard
- FDA guidanceRecommended in FDA’s draft guidance on protocol deviations
- Good practiceSupports a regulatory goal; how you meet it is up to you
Sources are listed at the end of the self-check.
0 of 10 answered
Your score
/ 10
Your study looks like the ones Vera was built for: deviations from several sources, assessments the EDC can't hold, and critical decisions that can't wait.
Your gaps, most weight first
This self-check is a conversation starter, not an audit or a regulatory assessment. Tags show where each question connects to FDA regulations, ICH E6(R3) or FDA’s December 2024 draft guidance on protocol deviations, which is nonbinding. Bionabu is not affiliated with or endorsed by FDA or ICH.
Sources · Last checked: 1 Oct 2026
ICH E6(R3) Good Clinical Practice: principles and Annex 1 in effect in the EU since 23 July 2025. Annex 2 (decentralised, pragmatic and real-world data trials) was adopted in June 2026 and takes effect on 15 January 2027.
FDA draft guidance Protocol Deviations for Clinical Investigations of Drugs, Biological Products, and Devices (December 2024, docket FDA-2023-D-5016). As of Oct 1, 2026, FDA lists it as current draft guidance, with no newer final or revised version. FDA regulations: 21 CFR 50 and 21 CFR 56.
Book a walkthrough
Bring us your study. We’ll map your clinical trial oversight.
30 minutes with Ina Burgstaller, founder, 20+ years in clinical trials. Built around your study.
We sign your NDA before you share anything.
Privacy questions: privacy@bionabu.com